Skip to main content

Advertisement

Table 2 Patient characteristics according to the rs1214194 genotype

From: Role of genetic variations of chitinase 3-like 1 in bronchial asthmatic patients

rs1214194 genotype GG (n = 170) GA (n = 157) AA (n = 41) P value
Age, years 57.8 ± 1.2 57.7 ± 1.3 58.4 ± 2.7 NS
Height, cm 158.8 ± 0.7 159.0 ± 0.7 157.7 ± 1.5 NS
Body weight, kg 60.5 ± 1.9 59.6 ± 1.0 59.1 ± 1.9 NS
Sex, n (%) 71 men (42) 71 men (45) 15 men (37) NS
Age of onset, years 43.5 ± 1.6 43.2 ± 1.7 34.2 ± 3.3 0.032
Eosinophil count/μL 315.6 ± 21.7 310.6 ± 23.4 331.7 ± 46.1 NS
IgE level, IU/mL 473.7 ± 97.5 504.4 ± 101.2 235.7 ± 199.2 NS
GINA asthma severity, n (%)
 Mild 35 (20.6) 34 (21.7) 4 (9.8)
 Moderate 70 (41.2) 61 (38.9) 18 (43.9)
 Severe 65 (38.2) 62 (39.5) 19 (46.3)
Pulmonary function
 %FVC 104.0 ± 2.6 104.0 ± 2.4 97.2 ± 5.9 NS
 FEV1, L 2.3 ± 0.1 2.3 ± 0.1 2.1 ± 0.2 NS
 FEV1/FVC, % 72.4 ± 0.9 72.2 ± 1.0 70.9 ± 1.8 NS
 %FEV1 99.6 ± 2.0 98.8 ± 1.8 87.9 ± 3.6 0.04
  Mild 106.7 ± 4.3 102.7 ± 3.8 91.0 ± 11.8
  Moderate 103.1 ± 3.0 99.3 ± 2.8 89.5 ± 5.6
  Severe 92.0 ± 3.1 95.1 ± 3.8 85.8 ± 5.4
 Equivalent FP CFC dose (μg/day) 325.6 ± 20.8 363.1 ± 22.3 432.1 ± 44.1 NS
  1. Data are expressed as the mean ± standard error
  2. GINA, Global Initiative for Asthma; FVC, forced vital capacity; FEV1, forced expiratory flow volume in one second; NS, not significant among the three groups; FP, fluticasone propionate; CFC, chlorofluorocarbon propellant